IP Library › Granted Patent US 10,143,651
Granted Patent B2
US 10,143,651 · App. 15/355,225 · Granted Dec 4, 2018

Amphiphilic polymer

Inventors: Su Jeong Kim (Daejeon, KR); Jeong Ae Yoon (Daejeon, KR); Sun Hwa Lee (Daejeon, KR); Woo Sun Shim (Daejeon, KR); Sung Soo Yoon (Daejeon, KR); Chang Hwan Ju (Daejeon, KR); Jung A Kim (Daejeon, KR); Nae Gyu Kang (Daejeon, KR)
Assignees: LG Chem, Ltd.; LG Household & Health Care Ltd.
A61K9/1075A61K31/352A61K47/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,143,651
App. No.
15/355,225
Granted
Dec 4, 2018
Kind
B2
Abstract

The present application relates to a micelle comprising a drug encapsulated by an amphiphilic polymer and a composition comprising the same. The micelle of the present application has an excellent dispersion property on an aqueous solution and a superior percutaneous absorption characteristic on preparing a formulation.

Claims (38)

1. A micelle comprising:

a drug; and

an amphiphilic polymer which encapsulates said drug, has a first block (A) and a second block (B) that is phase-separated with said first block (A) and comprises a polymerization unit (B1) of an acrylic monomer or a vinylic monomer having a solubility parameter of a single polymer of less than 10.0 (cal/cm 3 ) 1/2 and a polymerization unit (B2) of a polymerizable monomer having a functional group being capable of forming a hydrogen bond,

wherein the first block (A) comprises a polymer having a solubility parameter of 10 (cal/cm 3 ) 1/2 or more,

wherein a weight ratio (B1:B2) of the polymerization unit (B1) of an acrylic monomer or a vinylic monomer having a solubility parameter of a single polymer of less than 10.0 (cal/cm 3 ) 1/2 and the polymerization unit (B2) of a polymerizable monomer having a functional group being capable of forming a hydrogen bond, in the second block (B), is in a range of 1:9 to 9:1,

wherein the drug includes intramolecular —H, wherein the intramolecular —H forms a hydrogen bond with the functional group of polymerization unit (B2) in the second block (B) of the amphiphilic polymer.

2. The micelle according to claim 1 , wherein the drug comprises a physiologically active substance.

3. The micelle according to claim 2 , wherein the physiologically active substance is sparingly soluble.

4. The micelle according to claim 3 , wherein the sparingly soluble and physiologically active substance is any one selected from the group consisting of genistein, daidzein, cucurbitasin, prangenidin or a derivative thereof; a polyphenol; or a mixture thereof.

5. The micelle according to claim 4 , wherein the sparingly soluble and physiologically active substance is genistein or a glycoside of said genistein.

6. The micelle according to claim 1 , wherein the first block (A) is any one selected from the group consisting of polyethylene glycol, a polyethylene glycol-propylene glycol copolymer, polyvinyl pyrrolidone and polyethyleneimine.

7. The micelle according to claim 1 , wherein

the acrylic monomer is represented by Formula 1 or Formula 2 below:

where, Q in Formula 1 and 2 is hydrogen or an alkyl group, B in Formula 1 is a straight or branched alkyl group having at least one carbon atom, an alicyclic hydrocarbon group, an aromatic substituent or a carboxyl group, and R 1 and R 2 in Formula 2 are each independently hydrogen, a straight or branched alkyl group having at least one carbon atom, an alicyclic hydrocarbon group, or an aromatic substituent.

8. The micelle according to claim 7 , wherein

Q in Formula 1 is hydrogen or an alkyl group having 1 to 4 carbon atoms, B is an alkyl group having at least one carbon atom or an alicyclic hydrocarbon group having 6 to 12 carbon atoms.

9. The micelle according to claim 1 , wherein

the vinylic monomer is represented by Formula 3 or Formula 4 below:

where, X is a nitrogen atom or an oxygen atom, Y is a carbonyl group or a single bond, R 3 and R 5 are each independently hydrogen or an alkyl group, or R 3 and R 5 are linked together to form an alkylene group, and R 4 is an alkenyl group (provided that R 3 is not present, if X is an oxygen atom);

where, R 6 , R 7 and R 8 are each independently hydrogen or an alkyl group, and R 9 is a cyano group or an aromatic substituent.

10. The micelle according to claim 1 , wherein

the functional group is a hydroxyl group, an amine group, a nitro group, an amino group, an imide group, an alkoxysilane group or a cyano group.

11. The micelle according to claim 1 , wherein

the amphiphilic polymer has a block ratio (A:B) of the first block (A) and the second block (B) different from each other.

12. The micelle according to claim 11 , wherein

the block ratio (A:B) of the first block (A) and the second block (B) in the amphiphilic polymer is 1:9 to 9:1.

13. The micelle according to claim 1 , wherein

the block ratio (A:B) of the first block (A) and the second block (B) in the amphiphilic polymer is 3:7 to 7:3.

14. The micelle according to claim 1 , wherein

the second block of the amphiphilic polymer is adjacent to the drug.

15. The micelle according to claim 1 , wherein

the average particle diameter is in a range of 1 to 10,000 nm.

16. A composition for preparing particles comprising the micelle of claim 1 .

17. A pharmaceutical or cosmetic composition comprising the micelle of claim 1 .

18. The pharmaceutical or cosmetic composition according to claim 17 , wherein the composition is in a water-in-oil type emulsion form or an oil-in-water type emulsion form.

19. A process for preparing the micelle of claim 1 comprising:

a step of polymerizing a polymer forming a first block (A) and an acrylic monomer or a vinylic monomer having a solubility parameter of a single polymer of less than 10.0 (cal/cm 3 ) 1/2 to prepare an amphiphilic polymer; and

a step of mixing said amphiphilic polymer and a drug.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2016
From: KIM, SU JEONG; YOON, JEONG AE; LEE, SUN HWA; SHIM, WOO SUN; YOON, SUNG SOO; JU, CHANG HWAN; KIM, JUNG A.; KANG, NAE GYU
To: LG CHEM, LTD.; LG HOUSEHOLD & HEALTH CARE LTD.
Reel/Frame 041210/0938 →
Priority Claims (1)
KR 10-2015-0165869 · Nov 25, 2015 · national
Continuity (1)
Related Publication 20170143628A1 · May 25, 2017